Search

Your search keyword '"Morris, Huw"' showing total 1,506 results

Search Constraints

Start Over You searched for: Author "Morris, Huw" Remove constraint Author: "Morris, Huw"
1,506 results on '"Morris, Huw"'

Search Results

1. Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia.

2. Investigation of the genetic aetiology of Lewy body diseases with and without dementia

3. Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy

4. Network connectivity and structural correlates of survival in progressive supranuclear palsy and corticobasal syndrome.

5. Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes

6. Genome-wide determinants of mortality and motor progression in Parkinson’s disease

7. Genotype–phenotype correlation in PRKN-associated Parkinson’s disease

8. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

9. Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning.

10. Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups.

11. Current directions in tau research: Highlights from Tau 2020

12. RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses

13. MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study

14. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

16. Current directions in tau research: Highlights from Tau 2020.

17. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

19. Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

20. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study

21. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

23. Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

24. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

25. The parkinsonism dementia complex of Guam and flying foxes

27. MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study

29. The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy.

30. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

33. The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease

34. Multi-modality machine learning predicting Parkinson’s disease

35. Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study

36. Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo‐perceptual deficits

37. α‐Synuclein Pathology in PRKN‐Linked Parkinson's Disease: New Insights from a Blood‐Based Seed Amplification Assay

38. Distinct spatiotemporal atrophy patterns in corticobasal syndrome are associated with different underlying pathologies

39. The role of dopaminergic medication, lipid, and endocannabinoid pathway alterations in idiopathic andPRKN/PINK1-mediated Parkinson’s disease – a large-scale targeted metabolomics study

43. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study

44. Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases.

45. Which ante mortem clinical features predict progressive supranuclear palsy pathology?

46. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

47. ECONOMY CLASS.

48. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture

49. What is meant by the term tertiary education? Past developments and recent activity.

Catalog

Books, media, physical & digital resources